These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17674606)

  • 21. Uncertainty surrounds cancer vaccine review at FDA.
    Fox JL
    Nat Biotechnol; 2007 Aug; 25(8):827-8. PubMed ID: 17687346
    [No Abstract]   [Full Text] [Related]  

  • 22. Landmark approval for Dendreon's cancer vaccine.
    DeFrancesco L
    Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.
    Arlen PM; Wood LV
    Expert Rev Vaccines; 2012 Mar; 11(3):287-302. PubMed ID: 22380822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell vaccine hits FDA roadblock.
    Morrow T
    Manag Care; 2007 Jun; 16(6):52-3. PubMed ID: 17682740
    [No Abstract]   [Full Text] [Related]  

  • 25. Provenge approval means sensitive coverage decisions.
    Silverman E
    Manag Care; 2010 Sep; 19(9):31-4. PubMed ID: 20931888
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
    Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
    Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consultation corner. Prostate cancer vaccine offers new direction.
    Drake C
    Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
    [No Abstract]   [Full Text] [Related]  

  • 28. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.
    Gaines KK
    Urol Nurs; 2012; 32(2):95-8. PubMed ID: 22690466
    [No Abstract]   [Full Text] [Related]  

  • 29. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.
    Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED;
    Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
    McBride D
    ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
    [No Abstract]   [Full Text] [Related]  

  • 31. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Putting Provenge in perspective.
    Moul JW
    Oncology (Williston Park); 2011 Mar; 25(3):255, 258. PubMed ID: 21548468
    [No Abstract]   [Full Text] [Related]  

  • 33. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA approves prostate cancer "vaccine".
    Tanne JH
    BMJ; 2010 May; 340():c2431. PubMed ID: 20442242
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapy for the treatment of prostate cancer-a comeback?].
    De Santis M
    Urologe A; 2018 Nov; 57(11):1342-1345. PubMed ID: 30341689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer vaccine approval could open floodgates.
    Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
    [No Abstract]   [Full Text] [Related]  

  • 40. Sipuleucel-T (Provenge).
    Urol Nurs; 2012; 32(2):99. PubMed ID: 22690467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.